Prescription drug issues are back on the Washington's front-burner. IPI Resident Scholar Merrill Matthews talks with Dr. Robert Popovian about his new paper, which highlights how recent developments—including insulin pricing, PBMs, the Inflation Reduction Act and Medicaid—are moving the drug companies to reconsider how they price their products.
2023_05_25_Popovian_Drug_Prices